IDENTIFICATION OF PROGNOSTIC FACTORS OF THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CANCER

Cover Page

Cite item

Full Text

About the authors

B. Ya. Alekseyev

P.A. Herzen Moscow Oncology Research Institute;
Peoples’ Friendship University of Russia, Moscow

Email: dr.kalpinskiy@rambler.ru
Department of Urology with Course of Urologic Oncology Russian Federation

A. S. Kalpinsky

P.A. Herzen Moscow Oncology Research Institute;
Peoples’ Friendship University of Russia, Moscow

Author for correspondence.
Email: dr.kalpinskiy@rambler.ru
Department of Urology with Course of Urologic Oncology Russian Federation

K. M. Nyushko

P.A. Herzen Moscow Oncology Research Institute

Email: dr.kalpinskiy@rambler.ru
Russian Federation

A. A. Klimenko

Russian Radiology Research Center, Moscow

Email: dr.kalpinskiy@rambler.ru
Russian Federation

Yu. V. Anzhiganova

Krasnoyarsk Territorial Clinical Oncology Dispensary

Email: dr.kalpinskiy@rambler.ru
Russian Federation

S. A. Varlamov

Altai Territorial Oncology Dispensary, Barnaul

Email: dr.kalpinskiy@rambler.ru
Russian Federation

S. A. Bichurina

Regional Clinical Oncology Dispensary, Blagoveshchensk

Email: dr.kalpinskiy@rambler.ru
Russian Federation

L. A. Vasilyev

S.M. Kirov Military Medical Academy, Saint Petersburg

Email: dr.kalpinskiy@rambler.ru
Russian Federation

A. V. Arkhipov

Arkhangelsk Regional Clinical Oncology Dispensary

Email: dr.kalpinskiy@rambler.ru
Russian Federation

L. I. Gurina

Primorye Territorial Oncology Dispensary, Vladivostok

Email: dr.kalpinskiy@rambler.ru
Russian Federation

O. V. Leonov

Clinical Oncology Dispensary, Omsk

Email: dr.kalpinskiy@rambler.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.